|
US9833480B2
(en)
|
2010-04-14 |
2017-12-05 |
Prospect Chartercare, Llc |
Methods and compositions for treating HIV
|
|
US10426740B1
(en)
|
2010-08-18 |
2019-10-01 |
Avm Biotechnology, Llc |
Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
|
|
CN103442768A
(zh)
*
|
2011-01-18 |
2013-12-11 |
宾夕法尼亚大学董事会 |
治疗癌的组合物和方法
|
|
KR102247979B1
(ko)
|
2012-05-25 |
2021-05-04 |
셀렉티스 |
면역요법을 위한 동종이형 및 면역억제제 저항성인 ｔ 세포의 조작 방법
|
|
TW201414837A
(zh)
*
|
2012-10-01 |
2014-04-16 |
Univ Pennsylvania |
標定基質細胞以治療癌症之組合物和方法
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
US9598489B2
(en)
|
2012-10-05 |
2017-03-21 |
The Trustees Of The Univeristy Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
|
US9597357B2
(en)
|
2012-10-10 |
2017-03-21 |
Sangamo Biosciences, Inc. |
T cell modifying compounds and uses thereof
|
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
|
ES2949648T3
(es)
|
2012-12-20 |
2023-10-02 |
Purdue Research Foundation |
Células T que expresan un receptor antigénico quimérico como terapia contra el cáncer
|
|
JO3529B1
(ar)
|
2013-02-08 |
2020-07-05 |
Amgen Res Munich Gmbh |
مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد
|
|
PT3300745T
(pt)
|
2013-02-15 |
2019-11-27 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
|
US9573988B2
(en)
|
2013-02-20 |
2017-02-21 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
|
|
MX374929B
(es)
|
2013-02-20 |
2025-03-06 |
Novartis Ag |
RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
CA2907397C
(en)
|
2013-03-15 |
2022-11-22 |
Anthrogenesis Corporation |
Modified t lymphocytes
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
US11077144B2
(en)
|
2013-05-13 |
2021-08-03 |
Cellectis |
CD19 specific chimeric antigen receptor and uses thereof
|
|
MY172897A
(en)
*
|
2013-05-13 |
2019-12-13 |
Cellectis |
Cd19 specific chimeric antigen receptor and uses thereof
|
|
IL305656A
(en)
*
|
2013-09-23 |
2023-11-01 |
Wilson Wolf Mfg Corporation |
Improved methods for genetic modification in animal cells
|
|
CN103589742A
(zh)
*
|
2013-11-07 |
2014-02-19 |
申峰 |
嵌合体抗原受体胞内段的基因及其编码蛋白
|
|
US10640569B2
(en)
|
2013-12-19 |
2020-05-05 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3087101B1
(en)
|
2013-12-20 |
2024-06-05 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
JP2017504601A
(ja)
*
|
2013-12-20 |
2017-02-09 |
セレクティスＣｅｌｌｅｃｔｉｓ |
免疫療法のためにマルチインプットシグナル感受性ｔ細胞を操作する方法
|
|
EP4303229A3
(en)
*
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
EP3105335B1
(en)
*
|
2014-02-14 |
2019-10-02 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors and methods of making
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
HUE054588T2
(hu)
*
|
2014-04-07 |
2021-09-28 |
Novartis Ag |
Rák kezelése CD19 elleni, kiméra antigénreceptor alkalmazásával
|
|
JP6788573B6
(ja)
|
2014-04-10 |
2020-12-16 |
シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート |
メトトレキサートによる選択と組み合わせたＳｌｅｅｐｉｎｇ Ｂｅａｕｔｙトランスポゾンによる遺伝子改変Ｔ細胞の製造
|
|
CN106459924A
(zh)
*
|
2014-04-23 |
2017-02-22 |
得克萨斯州大学系统董事会 |
用于疗法中的嵌合抗原受体(car)及其制备方法
|
|
DK3134095T3
(da)
|
2014-04-25 |
2020-06-29 |
Bluebird Bio Inc |
Forbedrede fremgangsmåder til fremstilling af adoptive celleterapier
|
|
RU2708311C2
(ru)
|
2014-04-25 |
2019-12-05 |
Блубёрд Био, Инк. |
Химерные антигенные рецепторы с mnd-промотором
|
|
US10301370B2
(en)
|
2014-05-02 |
2019-05-28 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of chimeric autoantibody receptor T cells
|
|
SI3151672T1
(sl)
*
|
2014-06-06 |
2021-03-31 |
Bluebird Bio, Inc. |
Izboljšani T-celični sestavki
|
|
CN107109420A
(zh)
|
2014-07-21 |
2017-08-29 |
诺华股份有限公司 |
使用cll－1嵌合抗原受体的癌症治疗
|
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US9777061B2
(en)
|
2014-07-21 |
2017-10-03 |
Novartis Ag |
Treatment of cancer using a CD33 chimeric antigen receptor
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
US20170226216A1
(en)
|
2014-07-24 |
2017-08-10 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors
|
|
BR112017001818A2
(pt)
*
|
2014-07-29 |
2017-11-21 |
Pfizer |
receptores antigênicos quiméricos específicos para egfrviii para imunoterapia de câncer
|
|
PL3183268T3
(pl)
|
2014-08-19 |
2020-09-07 |
Novartis Ag |
Chimeryczny receptor antygenowy (CAR) anty-CD123 do zastosowania w leczeniu nowotworu złośliwego
|
|
DK4074735T3
(da)
*
|
2014-08-28 |
2025-07-14 |
Bioatla Inc |
Betinget aktive kimæriske antigenreceptorer til modificerede t-celler
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
WO2016044605A1
(en)
|
2014-09-17 |
2016-03-24 |
Beatty, Gregory |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
WO2016057705A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
CN107109438B
(zh)
*
|
2014-11-05 |
2021-09-03 |
朱诺治疗学股份有限公司 |
用于转导及细胞处理的方法
|
|
EP3640262A1
(en)
|
2014-12-12 |
2020-04-22 |
Bluebird Bio, Inc. |
Bcma chimeric antigen receptors for use in the treatment of a hematological malignancy
|
|
RU2017125531A
(ru)
|
2014-12-19 |
2019-01-21 |
Дана-Фарбер Кэнсер Инститьют, Инк. |
Химерные антигенные рецепторы и способы их применения
|
|
CA2972597A1
(en)
|
2014-12-29 |
2016-07-07 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
JP2018504145A
(ja)
|
2015-01-26 |
2018-02-15 |
セレクティスＣｅｌｌｅｃｔｉｓ |
再発性／難治性急性骨髄性リンパ腫または芽球性形質細胞様樹状細胞新生物を処置するための、ｃｄ１２３に結合するキメラ抗原受容体を賦与された、操作されたｔ細胞受容体ノックアウト免疫細胞
|
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
AU2016222887B2
(en)
|
2015-02-24 |
2022-07-14 |
The Regents Of The University Of California |
Binding-triggered transcriptional switches and methods of use thereof
|
|
EP3273976B1
(en)
|
2015-03-27 |
2023-07-26 |
President and Fellows of Harvard College |
Modified t cells and methods of making and using the same
|
|
CN119925616A
(zh)
|
2015-04-08 |
2025-05-06 |
诺华股份有限公司 |
Cd20疗法、cd22疗法和与cd19嵌合抗原受体（car）表达细胞的联合疗法
|
|
ES2948133T3
(es)
|
2015-04-17 |
2023-08-31 |
Novartis Ag |
Métodos para mejorar la eficacia y expansión de células que expresan un receptor de antígeno quimérico
|
|
US12128069B2
(en)
|
2015-04-23 |
2024-10-29 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
ES2973118T3
(es)
*
|
2015-05-13 |
2024-06-18 |
Csl Behring Gene Therapy Inc |
Bio-producción de vectores lentivirales
|
|
JP2018515123A
(ja)
|
2015-05-18 |
2018-06-14 |
ティーシーアール２ セラピューティクス インク． |
融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法
|
|
KR20250139881A
(ko)
|
2015-05-28 |
2025-09-23 |
카이트 파마 인코포레이티드 |
T 세포 요법을 위해 환자를 컨디셔닝하는 방법
|
|
SG10201913620QA
(en)
|
2015-05-28 |
2020-03-30 |
Kite Pharma Inc |
Diagnostic methods for t cell therapy
|
|
US10071118B2
(en)
*
|
2015-07-16 |
2018-09-11 |
Prospect Charactercare Rwmc, Llc |
Compositions and methods for treating peritoneal cancers
|
|
TWI859112B
(zh)
|
2015-07-21 |
2024-10-21 |
瑞士商諾華公司 |
改良免疫細胞之功效及擴展之方法
|
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
|
CA2994829A1
(en)
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
JP6905163B2
(ja)
|
2015-09-03 |
2021-07-21 |
ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア |
サイトカイン放出症候群を予測するバイオマーカー
|
|
SG11201802966TA
(en)
|
2015-10-20 |
2018-05-30 |
Kite Pharma Inc |
Methods of preparing t cells for t cell therapy
|
|
US10934525B2
(en)
|
2015-10-30 |
2021-03-02 |
Children's National Medical Center |
Generating HPV antigen-specific cells from a naive T cell population
|
|
CN105331585A
(zh)
*
|
2015-11-13 |
2016-02-17 |
科济生物医药（上海）有限公司 |
携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
|
|
LT3377618T
(lt)
*
|
2015-11-19 |
2021-02-10 |
Novartis Ag |
Buferiai, skirti lentivirusiniams preparatams stabilizuoti
|
|
EP3377523A4
(en)
*
|
2015-11-19 |
2019-06-19 |
The Regents of The University of California |
CONDITIONALLY REPRIMATABLE IMMUNOCELL RECEPTORS AND METHOD FOR USE THEREOF
|
|
JP6976960B2
(ja)
|
2015-11-27 |
2021-12-08 |
カーサリクス プロプライエタリー リミテッド |
遺伝子改変された細胞およびその使用
|
|
CA3006432A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US11479755B2
(en)
|
2015-12-07 |
2022-10-25 |
2Seventy Bio, Inc. |
T cell compositions
|
|
GB201522097D0
(en)
|
2015-12-15 |
2016-01-27 |
Cellular Therapeutics Ltd |
Cells
|
|
CN109069597A
(zh)
|
2015-12-22 |
2018-12-21 |
诺华股份有限公司 |
间皮素嵌合抗原受体(car)和抗pd-l1抗体抑制剂联用于抗癌治疗
|
|
CN109310727B
(zh)
|
2016-01-08 |
2022-09-27 |
加利福尼亚大学董事会 |
有条件活性的异二聚体多肽及其使用方法
|
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
SG10201912515XA
(en)
|
2016-04-01 |
2020-02-27 |
Kite Pharma Inc |
Bcma binding molecules and methods of use thereof
|
|
ES2930058T3
(es)
|
2016-04-01 |
2022-12-05 |
Kite Pharma Inc |
Receptores quiméricos y métodos de uso de los mismos
|
|
TWI787599B
(zh)
|
2016-04-01 |
2022-12-21 |
美商凱特製藥公司 |
嵌合抗原和ｔ細胞受體及使用方法
|
|
WO2017177149A2
(en)
|
2016-04-08 |
2017-10-12 |
Purdue Research Foundation |
Methods and compositions for car t cell therapy
|
|
US11446398B2
(en)
|
2016-04-11 |
2022-09-20 |
Obsidian Therapeutics, Inc. |
Regulated biocircuit systems
|
|
KR102529012B1
(ko)
|
2016-04-22 |
2023-05-09 |
크라제 메디컬 씨오 리미티드 |
세포성 면역요법을 위한 조성물 및 방법
|
|
WO2017186121A1
(zh)
*
|
2016-04-26 |
2017-11-02 |
科济生物医药（上海）有限公司 |
一种改善免疫应答细胞功能的方法
|
|
SMT202200432T1
(it)
|
2016-05-13 |
2022-11-18 |
Bioatla Inc |
Anticorpi, frammenti anticorpali anti-ror2, loro immunoconiugati e loro usi
|
|
JP7158104B2
(ja)
|
2016-07-15 |
2022-10-21 |
ビラクタ セラピューティクス，インク． |
Ｎｋ細胞ベースの療法で使用するためのｈｄａｃ阻害剤
|
|
WO2018022945A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd112 variant immunomodulatory proteins and uses thereof
|
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
|
WO2018022946A1
(en)
|
2016-07-28 |
2018-02-01 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
|
EP3494138A1
(en)
|
2016-08-02 |
2019-06-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
|
AU2017332161B9
(en)
|
2016-09-21 |
2024-08-22 |
The United States Government As Represented By The Department Of Veterans Affairs |
Chimeric antigen receptor (car) that targets chemokine receptor CCR4 and its use
|
|
IL292551B2
(en)
|
2016-10-07 |
2023-10-01 |
Tcr2 Therapeutics Inc |
Preparations and methods for reprogramming T-cell receptors using fusion proteins
|
|
EP3523331A1
(en)
|
2016-10-07 |
2019-08-14 |
Novartis AG |
Chimeric antigen receptors for the treatment of cancer
|
|
US11331380B2
(en)
|
2016-10-20 |
2022-05-17 |
Celgene Corporation |
Cereblon-based heterodimerizable chimeric antigen receptors
|
|
CN110352245A
(zh)
|
2016-10-20 |
2019-10-18 |
高山免疫科学股份有限公司 |
可分泌变体免疫调节蛋白和工程化细胞疗法
|
|
AU2017355504C1
(en)
|
2016-11-04 |
2024-06-20 |
2Seventy Bio, Inc. |
Anti-BCMA CAR T cell compositions
|
|
AU2017363311A1
(en)
|
2016-11-22 |
2019-06-13 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
|
AU2017375630B2
(en)
|
2016-12-12 |
2023-12-21 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
|
|
GB201700621D0
(en)
|
2017-01-13 |
2017-03-01 |
Guest Ryan Dominic |
Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
CN106749681A
(zh)
*
|
2017-02-10 |
2017-05-31 |
河南大学淮河医院 |
靶向人FRα的基因工程化NKT细胞及其制备方法和应用
|
|
PT3583129T
(pt)
|
2017-02-14 |
2021-12-14 |
Kite Pharma Inc |
Moléculas de ligação a cd70 e seus métodos de uso
|
|
ES3010559T3
(en)
|
2017-02-28 |
2025-04-03 |
Endocyte Inc |
Compositions and methods for car t cell therapy
|
|
WO2018169922A2
(en)
|
2017-03-13 |
2018-09-20 |
Kite Pharma, Inc. |
Chimeric antigen receptors for melanoma and uses thereof
|
|
AU2018236224B2
(en)
|
2017-03-16 |
2024-01-04 |
Alpine Immune Sciences, Inc. |
PD-L1 variant immunomodulatory proteins and uses thereof
|
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
|
JP7386083B2
(ja)
|
2017-03-16 |
2023-11-24 |
アルパイン イミューン サイエンシズ インコーポレイテッド |
Ｃｄ８０バリアント免疫調節タンパク質及びその使用
|
|
SG11201907434RA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
MX2019011656A
(es)
*
|
2017-03-27 |
2019-12-02 |
Hoffmann La Roche |
Formatos mejorados de receptor de union a antigeno.
|
|
CA3054443A1
(en)
|
2017-04-01 |
2018-10-14 |
Avm Biotechnology, Llc |
Replacement of cytotoxic preconditioning before cellular immunotherapy
|
|
TW201902493A
(zh)
|
2017-04-03 |
2019-01-16 |
美商凱特製藥公司 |
使用併入最佳化多功能t細胞之嵌合受體t細胞之治療
|
|
JP2020517259A
(ja)
|
2017-04-19 |
2020-06-18 |
ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム |
操作された抗原受容体を発現する免疫細胞
|
|
JOP20180042A1
(ar)
|
2017-04-24 |
2019-01-30 |
Kite Pharma Inc |
نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام
|
|
US11778994B2
(en)
*
|
2017-05-12 |
2023-10-10 |
The Jackson Laboratory |
NSG mice lacking MHC class I and class II
|
|
CA3061959A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
|
|
AU2018292181B2
(en)
|
2017-06-30 |
2025-04-10 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
CA3070579A1
(en)
*
|
2017-08-09 |
2019-02-14 |
Juno Therapeutics, Inc. |
Methods for producing genetically engineered cell compositions and related compositions
|
|
CN114533863A
(zh)
*
|
2017-09-15 |
2022-05-27 |
凯德药业股份有限公司 |
用于进行具有监管链和身份链生物样品跟踪的患者特异性免疫疗法规程的方法和系统
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
WO2019060695A1
(en)
|
2017-09-22 |
2019-03-28 |
Kite Pharma, Inc. |
CHIMERIC POLYPEPTIDES AND USES THEREOF
|
|
KR102758545B1
(ko)
|
2017-10-10 |
2025-01-23 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Ctla-4 변이체 면역조절 단백질 및 이의 용도
|
|
SG11202003415XA
(en)
|
2017-10-18 |
2020-05-28 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
US11712026B2
(en)
|
2017-10-18 |
2023-08-01 |
The Jackson Laboratory |
Murine-MHC-deficient HLA-transgenic nod-mouse models for T1D therapy development
|
|
US20190151361A1
(en)
|
2017-10-18 |
2019-05-23 |
Kite Pharma, Inc. |
Methods of administering chimeric antigen receptor immunotherapy
|
|
TW202500579A
(zh)
|
2017-10-18 |
2025-01-01 |
美商艾爾潘免疫科學有限公司 |
變異型icos 配位體免疫調節蛋白及相關組合物及方法
|
|
EP3707160A1
(en)
|
2017-11-10 |
2020-09-16 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting tumor antigens
|
|
WO2019099707A1
(en)
|
2017-11-16 |
2019-05-23 |
Kite Pharma, Inc |
Modified chimeric antigen receptors and methods of use
|
|
GB201721833D0
(en)
*
|
2017-12-22 |
2018-02-07 |
Cancer Research Tech Ltd |
Fusion proteins
|
|
CN111867619A
(zh)
|
2018-01-03 |
2020-10-30 |
曲生物制品公司 |
过继性细胞治疗的先天寻靶
|
|
SG11202006148UA
(en)
|
2018-01-03 |
2020-07-29 |
Alpine Immune Sciences Inc |
Multi-domain immunomodulatory proteins and methods of use thereof
|
|
CN111867680A
(zh)
|
2018-01-15 |
2020-10-30 |
辉瑞大药厂 |
组合施用嵌合抗原受体免疫疗法与4-1bb激动剂的方法
|
|
TW201940182A
(zh)
|
2018-01-22 |
2019-10-16 |
美商安德賽特公司 |
Car t 細胞之使用方法
|
|
US20210040449A1
(en)
|
2018-02-16 |
2021-02-11 |
Kite Pharma, Inc. |
Modified pluripotent stem cells and methods of making and use
|
|
US12473336B2
(en)
|
2018-02-21 |
2025-11-18 |
Board Of Regents, The University Of Texas System |
Methods for activation and expansion of natural killer cells and uses thereof
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
US10780120B2
(en)
|
2018-03-06 |
2020-09-22 |
The Trustees Of The University Of Pennsylvania |
Prostate-specific membrane antigen cars and methods of use thereof
|
|
CA3091683A1
(en)
|
2018-03-13 |
2019-09-19 |
Phanes Therapeutics, Inc. |
Anti-folate receptor 1 antibodies and uses thereof
|
|
DE102018108612A1
(de)
|
2018-03-21 |
2019-09-26 |
Immatics US, Inc. |
Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
|
|
CN112218888A
(zh)
|
2018-04-12 |
2021-01-12 |
凯德药业股份有限公司 |
使用肿瘤微环境的特征的嵌合受体t细胞治疗
|
|
US10869888B2
(en)
|
2018-04-17 |
2020-12-22 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expansion and uses thereof
|
|
JP7174777B2
(ja)
|
2018-06-01 |
2022-11-17 |
カイト ファーマ インコーポレイテッド |
キメラ抗原受容体ｔ細胞療法
|
|
US11905321B2
(en)
|
2018-06-05 |
2024-02-20 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of muscle specific kinase chimeric autoantibody receptor cells
|
|
US20220403001A1
(en)
|
2018-06-12 |
2022-12-22 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
CA3100724A1
(en)
|
2018-06-13 |
2019-12-19 |
Novartis Ag |
B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
|
|
WO2019241758A1
(en)
|
2018-06-15 |
2019-12-19 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
|
US20210269501A1
(en)
*
|
2018-06-25 |
2021-09-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of nkg2d chimeric antigen receptor t cells for controlling triple-negative breast cancer
|
|
WO2020016661A2
(en)
*
|
2018-07-09 |
2020-01-23 |
Multitude Inc. |
Antibodies specific to folate receptor alpha
|
|
EP3830125A1
(en)
|
2018-08-02 |
2021-06-09 |
Kite Pharma, Inc. |
Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof
|
|
CN110819703A
(zh)
*
|
2018-08-07 |
2020-02-21 |
上海恒润达生生物科技有限公司 |
一种评估cart细胞安全性的方法
|
|
US12240915B2
(en)
|
2018-08-30 |
2025-03-04 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Chimeric antigen receptor cells for treating solid tumor
|
|
US11866494B2
(en)
*
|
2018-08-31 |
2024-01-09 |
Innovative Cellular Therapeutics Holdings, Ltd. |
CAR T therapy through uses of co-stimulation
|
|
CN113544144A
(zh)
|
2018-09-19 |
2021-10-22 |
高山免疫科学股份有限公司 |
变体cd80融合蛋白和相关构建体的方法和用途
|
|
CA3113618A1
(en)
|
2018-09-28 |
2020-04-02 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
EP3488851A1
(en)
|
2018-10-03 |
2019-05-29 |
AVM Biotechnology, LLC |
Immunoablative therapies
|
|
MX2021004058A
(es)
*
|
2018-10-10 |
2021-06-04 |
Zymeworks Inc |
Construcciones de anticuerpos que se unen a 4-1bb y a antigenos asociados a tumores y sus usos.
|
|
CN116286665A
(zh)
*
|
2018-11-16 |
2023-06-23 |
上海煦顼技术有限公司 |
嵌合抗原受体细胞分泌治疗剂
|
|
US10918667B2
(en)
|
2018-11-20 |
2021-02-16 |
Innovative Cellular Therapeutics CO., LTD. |
Modified cell expressing therapeutic agent and uses thereof
|
|
US20220000921A1
(en)
*
|
2018-11-20 |
2022-01-06 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Modified Cell Expressing Therapeutic Agent and Uses thereof
|
|
CA3118511C
(en)
|
2018-11-29 |
2024-04-30 |
Vineti Inc. |
Centralized and decentralized individualized medicine platform
|
|
US12227551B2
(en)
|
2018-12-11 |
2025-02-18 |
Obsidian Therapeutics, Inc. |
Membrane bound IL12 compositions and methods for tunable regulation
|
|
KR20250116790A
(ko)
|
2018-12-12 |
2025-08-01 |
카이트 파마 인코포레이티드 |
키메라 항원 수용체 및 car-t 세포 및 사용 방법
|
|
CN109796535B
(zh)
*
|
2019-01-30 |
2022-11-15 |
重庆福美干细胞生物科技发展有限公司 |
靶向叶酸受体α的嵌合抗原受体及其在制备预防或治疗恶性肿瘤药物中的用途
|
|
US11321652B1
(en)
|
2019-02-20 |
2022-05-03 |
Vineti Inc. |
Smart label devices, systems, and methods
|
|
MX2021010840A
(es)
|
2019-03-08 |
2022-01-19 |
Obsidian Therapeutics Inc |
Composiciones de anhidrasa carbónica 2 (ca2) humana y métodos de regulación ajustable.
|
|
CN113661180B
(zh)
*
|
2019-03-27 |
2025-08-26 |
宾夕法尼亚大学董事会 |
Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
|
|
CN118593691A
(zh)
|
2019-05-03 |
2024-09-06 |
凯德药业股份有限公司 |
施用嵌合抗原受体免疫疗法的方法
|
|
WO2020231999A1
(en)
*
|
2019-05-13 |
2020-11-19 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells
|
|
WO2020234632A1
(en)
|
2019-05-23 |
2020-11-26 |
Ichorlabs, D.O.O |
Method for removal of nucleic acids impurities from liquid composition comprising genetically engineered particles or proteins
|
|
BR112021025022A2
(pt)
|
2019-06-12 |
2022-02-22 |
Obsidian Therapeutics Inc |
Composições de ca2 e métodos para regulação ajustáveis
|
|
EP3983537A1
(en)
|
2019-06-12 |
2022-04-20 |
Obsidian Therapeutics, Inc. |
Ca2 compositions and methods for tunable regulation
|
|
CA3143271A1
(en)
|
2019-06-21 |
2020-12-24 |
Kite Pharma, Inc. |
Tgf-.beta. receptors and methods of use
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
GB201909573D0
(en)
|
2019-07-03 |
2019-08-14 |
Cancer Research Tech Ltd |
Modulation of T cell cytotoxicity and related therapy
|
|
WO2021046134A1
(en)
|
2019-09-03 |
2021-03-11 |
Allogene Therapeutics, Inc. |
Methods of preparing t cells for t cell therapy
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
CA3154280A1
(en)
*
|
2019-10-11 |
2021-04-15 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for targeting cd13 and tim-3 with car t cells to treat acute myeloid leukemia
|
|
KR20220143634A
(ko)
*
|
2019-10-16 |
2022-10-25 |
우모자 바이오파마 인코포레이티드 |
보편적 수용체 요법을 위한 레트로바이러스 벡터
|
|
AU2020394441B2
(en)
|
2019-11-26 |
2025-11-13 |
Novartis Ag |
CD19 and CD22 chimeric antigen receptors and uses thereof
|
|
IL293215A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors that bind bcma and cd19 and their uses
|
|
EP4077641A1
(en)
|
2019-12-20 |
2022-10-26 |
Instil Bio (Uk) Limited |
Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
|
|
US12076343B2
(en)
|
2020-02-19 |
2024-09-03 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Engineered safety in cell therapy
|
|
WO2021183675A2
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Methods for generating engineered memory-like nk cells and compositions thereof
|
|
CA3173981A1
(en)
|
2020-03-10 |
2021-09-16 |
Massachusetts Institute Of Technology |
Compositions and methods for immunotherapy of npm1c-positive cancer
|
|
GB202005599D0
(en)
|
2020-04-17 |
2020-06-03 |
Univ London |
Modulation of t cell cytotoxicity and related therapy
|
|
GB202006254D0
(en)
|
2020-04-28 |
2020-06-10 |
Institute Of Cancer Res |
Anti-cancer vaccines and related therapy
|
|
WO2021221782A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
US12043654B2
(en)
|
2020-06-02 |
2024-07-23 |
Innovative Cellular Therapeutics Holdings, Ltd. |
Anti-GCC antibody and CAR thereof for treating digestive system cancer
|
|
US20230293530A1
(en)
|
2020-06-24 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Agents for sensitizing solid tumors to treatment
|
|
WO2022016112A1
(en)
|
2020-07-17 |
2022-01-20 |
Instil Bio (Uk) Limited |
Receptors providing targeted costimulation for adoptive cell therapy
|
|
JP7524465B2
(ja)
|
2020-08-14 |
2024-07-29 |
カイト ファーマ インコーポレイテッド |
免疫細胞機能の改善
|
|
JP2023541368A
(ja)
*
|
2020-08-18 |
2023-10-02 |
デルフィ ダイアグノスティックス インコーポレイテッド |
がんを評価するための無細胞ｄｎａ断片サイズ密度のための方法及びシステム
|
|
EP4204545A2
(en)
|
2020-08-25 |
2023-07-05 |
Kite Pharma, Inc. |
T cells with improved functionality
|
|
KR20230074758A
(ko)
|
2020-09-24 |
2023-05-31 |
더 잭슨 래보라토리 |
면역 세포 요법을 평가하기 위한 인간화 마우스 모델
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
WO2022140159A1
(en)
|
2020-12-24 |
2022-06-30 |
Kite Pharma, Inc. |
Prostate cancer chimeric antigen receptors
|
|
WO2022150582A1
(en)
|
2021-01-10 |
2022-07-14 |
Kite Pharma, Inc. |
T cell therapy
|
|
JP2024507199A
(ja)
|
2021-02-20 |
2024-02-16 |
カイト ファーマ インコーポレイテッド |
免疫療法を選択するための遺伝子マーカー
|
|
AU2022234333B2
(en)
|
2021-03-11 |
2025-05-22 |
Kite Pharma, Inc. |
Improving immune cell function
|
|
CN112794911B
(zh)
*
|
2021-04-14 |
2021-08-03 |
上海偌妥生物科技有限公司 |
人源化抗叶酸受体1抗体及其应用
|
|
AU2022259428A1
(en)
|
2021-04-16 |
2023-10-26 |
Kite Pharma, Inc. |
Taci/bcma dual binding molecules
|
|
TW202309269A
(zh)
|
2021-04-27 |
2023-03-01 |
日商武田藥品工業股份有限公司 |
重組抗原呈現細胞
|
|
WO2022241151A2
(en)
|
2021-05-14 |
2022-11-17 |
Kite Pharma, Inc. |
Chimeric antigen receptor t cell therapy
|
|
IL308696A
(en)
|
2021-05-24 |
2024-01-01 |
Kite Pharma Inc |
Nkg2d-based chimeric antgen receptor
|
|
WO2022261018A1
(en)
|
2021-06-07 |
2022-12-15 |
Providence Health & Services - Oregon |
Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
|
|
WO2022261061A1
(en)
|
2021-06-08 |
2022-12-15 |
Kite Pharma, Inc. |
Gpc3 binding molecules
|
|
TW202306997A
(zh)
|
2021-06-16 |
2023-02-16 |
英商英斯特生物科技有限公司 |
用於在過繼細胞療法中提供標靶共刺激之受體
|
|
US20230027004A1
(en)
|
2021-07-01 |
2023-01-26 |
Kite Pharma, Inc. |
Closed-system and method for autologous and allogeneic cell therapy manufacturing
|
|
CA3224722A1
(en)
|
2021-07-02 |
2023-01-05 |
Kite Pharma, Inc. |
A method for identifying variants in gene products from gene constructs used in cell therapy applications
|
|
WO2023288278A1
(en)
|
2021-07-16 |
2023-01-19 |
Instil Bio (Uk) Limited |
Chimeric molecules providing targeted costimulation for adoptive cell therapy
|
|
US11615874B1
(en)
|
2021-09-30 |
2023-03-28 |
Vineti Inc. |
Personalized medicine and therapies platform
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
EP4456927A1
(en)
|
2021-12-30 |
2024-11-06 |
TR1X, Inc. |
Cd4t cells expressing il-10 and chimeric antigen receptors and uses thereof
|
|
CA3247928A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
CA3247927A1
(en)
|
2022-01-14 |
2023-07-20 |
Tune Therapeutics, Inc. |
Compositions, systems and methods for programming T-lymphocyte phenotypes by targeted gene repression
|
|
CA3259019A1
(en)
|
2022-02-15 |
2023-08-24 |
Kite Pharma, Inc. |
PREDICTION OF ADVERSE EVENTS FROM IMMUNOTHERAPY
|
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
|
KR20250017239A
(ko)
|
2022-06-09 |
2025-02-04 |
카이트 파마 인코포레이티드 |
세포 치료를 위한 림프구 제조 방법
|
|
WO2024033879A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Hypoimmunogenic modified cells
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
EP4608987A1
(en)
|
2022-10-28 |
2025-09-03 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy
|
|
US20240165160A1
(en)
|
2022-10-28 |
2024-05-23 |
Kite Pharma, Inc. |
Efficacy and durable response of immunotherapy
|
|
CN120917153A
(zh)
|
2023-03-17 |
2025-11-07 |
凯德药业股份有限公司 |
肿瘤微环境对免疫疗法疗效的影响
|
|
WO2024206549A2
(en)
*
|
2023-03-29 |
2024-10-03 |
Cellicure, Inc. |
Engineered immune cells and use thereof
|
|
TW202506996A
(zh)
|
2023-04-27 |
2025-02-16 |
日商武田藥品工業股份有限公司 |
擴增ｃｄ５６＋／ｃｄ３－細胞之方法
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
US20250161361A1
(en)
|
2023-11-01 |
2025-05-22 |
Kite Pharma, Inc. |
Factors for optimizing immunotherapy efficacy
|
|
WO2025188561A1
(en)
|
2024-03-04 |
2025-09-12 |
Kite Pharma, Inc. |
Predictive markers for immunotherapy
|
|
WO2026015450A1
(en)
|
2024-07-06 |
2026-01-15 |
Tr1X, Inc. |
Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof
|